Pathological Response After Neoadjuvant Treatment on NSCLC

NCT05167487 · clinicaltrials.gov ↗

RECRUITING

Status

150

Enrollment

OTHER

Sponsor class

Conditions

Stage IIIA Non-small Cell Lung Cancer

Interventions

DRUG: Cisplatin
DRUG: Carboplatin

Sponsor

Fundación GECP